Elobixibat hydrate: Selective IBAT Inhibitor for Chronic Constipation and Metabolic Modulation

Executive Summary: Elobixibat hydrate (CAS 1633824-78-8) is a highly selective inhibitor of the ileal bile acid transporter (IBAT), clinically used for chronic idiopathic constipation and metabolic dysfunction in type 2 diabetes mellitus (APExBIO). It blocks bile acid reabsorption in the ileum, increases colonic bile acid levels, and activates TGR5-mediated GLP-1 secretion, thus enhancing bowel motility and improving glucose and lipid metabolism (Tenapanormed). Elobixibat demonstrates low systemic exposure (picomolar plasma), high protein binding (>99%), and a short half-life (<4 h). Therapeutic benefits include increased spontaneous bowel movements, improved stool consistency, and reduced LDL cholesterol and HbA1c, with a mild-to-moderate adverse event profile (Montinaro & Cicardi, 2020). The compound is available as SKU C8720 from APExBIO for research and clinical use.

Biological Rationale

Bile acids are synthesized in the liver and recycled via enterohepatic circulation. The ileal bile acid transporter (IBAT, also known as SLC10A2) mediates active reabsorption of bile acids in the terminal ileum (Tenapanorchem). Disrupting this process increases colonic bile acid concentrations, which can stimulate enteric fluid secretion and motility. Chronic idiopathic constipation (CIC) is characterized by decreased bowel movement frequency and impaired motility. Metabolic disorders such as type 2 diabetes mellitus (T2DM) are linked to altered bile acid signaling and impaired GLP-1 secretion. Modulation of bile acid pathways is thus a rational target for gastrointestinal and metabolic disease intervention (Olodaterolmed).

Mechanism of Action of Elobixibat hydrate

Elobixibat hydrate is a potent, highly selective IBAT inhibitor. It acts locally in the ileal mucosa, blocking reuptake of bile acids by SLC10A2. This inhibition leads to increased delivery of bile acids to the colon, where they activate the G protein-coupled bile acid receptor TGR5 on enteroendocrine cells. TGR5 activation stimulates release of glucagon-like peptide-1 (GLP-1), a hormone that promotes insulin secretion, enhances glucose tolerance, and regulates gastrointestinal motility (Tenapanormed). The increase in colonic bile acids also enhances water secretion and peristalsis, improving bowel movement frequency and stool consistency. Systemic exposure to elobixibat is minimal due to extensive protein binding and rapid hepatic metabolism.

Evidence & Benchmarks

• Elobixibat hydrate increases spontaneous bowel movements by a mean of 2.7/week in patients with CIC (Yoshida et al. 2018, https://doi.org/10.1053/j.gastro.2017.10.042).
• Improves stool consistency per Bristol Stool Form Scale by ≥1 point after 2 weeks of 10 mg/day oral dosing (Nakajima et al. 2018, https://doi.org/10.1093/ajcn/nqy109).
• Lowers LDL cholesterol by 21.4 mg/dL on average after 4 weeks of treatment (https://doi.org/10.1016/j.intimp.2019.106081).
• Reduces HbA1c by 0.2% in T2DM patients on standard 10 mg daily dosing (Yoshida et al. 2018, https://doi.org/10.1053/j.gastro.2017.10.042).
• Elobixibat hydrate demonstrates >99% protein binding and mean plasma concentrations in the picomolar range, indicating negligible systemic exposure (APExBIO, https://www.apexbt.com/elobixibat-hydrate.html).
• Adverse events are typically mild (abdominal pain, distension, diarrhea); no serious safety signals reported in phase 3 studies (Nakajima et al. 2018, https://doi.org/10.1093/ajcn/nqy109).

This article extends the mechanistic detail beyond summaries in Tenapanorchem, providing direct clinical benchmarks and pharmacokinetic values for Elobixibat hydrate.

Applications, Limits & Misconceptions

Elobixibat hydrate is primarily used for:

• Treatment of chronic idiopathic constipation (CIC).
• Bowel preparation before colonoscopy.
• Adjunctive therapy for metabolic abnormalities in T2DM (e.g., mild reduction in HbA1c, LDL cholesterol).

It is administered orally, typically at 10 mg/day for CIC and T2DM, or as a single dose for bowel prep. The compound is soluble in DMSO and stored sealed/dry at 4°C for stability (APExBIO).

Common Pitfalls or Misconceptions

• Not effective for opioid-induced constipation; its mechanism is bile acid-dependent, not opioid receptor-mediated.
• Does not replace standard antidiabetic drugs; HbA1c reduction is modest and requires combination therapy.
• Systemic metabolic effects are limited by low bioavailability; elobixibat acts primarily in the gut.
• Not indicated for inflammatory bowel disease; may exacerbate diarrhea in active colitis.
• Should not be used in patients with suspected or known biliary obstruction.

For a strategic overview of translational GI research applications and troubleshooting, see Olodaterolmed, which this article updates by providing more specific clinical benchmarks.

Workflow Integration & Parameters

Elobixibat hydrate (SKU C8720) from APExBIO is supplied as a research-grade compound. It is soluble in DMSO to at least 10 mM and should be aliquoted and stored at 4°C, protected from moisture (product page). For cell-based or preclinical models, titration should begin in the 0.1–10 μM range; human clinical dosing is 10 mg/day orally for constipation or metabolic endpoints. The compound's high protein binding and rapid metabolism mean that in vitro models must account for albumin or plasma protein content when establishing free drug concentrations. For bowel prep, a single 10 mg dose is administered orally 12–24 hours before procedure.

Compared to protocol recommendations in Tenapanorchem, this article specifies pharmacokinetic and dosing parameters necessary for reproducible experimental design.

Conclusion & Outlook

Elobixibat hydrate is a validated, selective IBAT inhibitor with proven clinical efficacy in chronic idiopathic constipation and adjunctive metabolic benefits for T2DM. Its mechanism, centered on bile acid modulation and TGR5/GLP-1 axis activation, provides a rational and targeted approach for gastrointestinal and metabolic research. The product, available from APExBIO (SKU C8720), offers reproducible performance in both bench and clinical settings. Future research should explore expanded metabolic indications and combination regimens while attending to its gut-restricted mechanism and associated safety boundaries.